From a patient-centric, clinical profile perspective, which “high risk burden” patient populations do you, as an atherosclerosis specialist, single out for PCSK9-mediated LDL-C reduction?

From a patient-centric, clinical profile perspective, which “high risk burden” patient populations do you, as an atherosclerosis specialist, single out for PCSK9-mediated LDL-C reduction?

CLICK HERE FOR CME CREDIT

From a patient-centric, clinical profile perspective, which “high risk burden” patient populations do you, as an atherosclerosis specialist, single out for PCSK9-mediated LDL-C reduction?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

Christie Ballantyne, MD

Christie Ballantyne, MD

Director, Center for Cardiovascular Disease Prevention Methodist DeBakey Heart Center Chief of the Section of Cardiovascular Research Baylor College of Medicine Director of Atherosclerosis Laboratory Professor of Medicine Baylor College of Medicine Houston, TX